Global Viral Partnering 2010-2017: Deal Trends, Players and Financials - Access to Headline, Upfront, Milestone and Royalty Data -- Research and Markets
Global Viral Partnering 2010 to 2017 provides the full collection of Viral disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.
The report takes readers through the comprehensive Viral disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Viral deals.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report presents financial deal terms values for Viral deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report scope:
Trends in Viral dealmaking in the biopharma industry since 2010
Analysis of Viral deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Viral deal contract documents
Comprehensive access to over 3500 Viral deal records
The leading Viral deals by value since 2010
Most active Viral dealmakers since 2010
The report includes deals for the following indications:
Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1 (Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio, Respiratory syncytial virus (RSV), Zika, plus other viral indications.
Global Viral Partnering 2010 to 2017 provides the reader with the following key benefits:
In-depth understanding of Viral deal trends since 2010
Access Viral deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between Viral partner companies
Comprehensive access to over 750 links to actual Viral deals entered into by the world's biopharma companies
Indepth review of Viral deals entered into by the top 25 most active dealmakers
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner Viral opportunities
The "Europe
Welding Equipment Market-Growth, Trends, and Forecast (2019 - 2024)"
report has been added to ResearchAndMarkets.com's
offering.
Welding is one of the critical processes employed in the manufacturing...
Inovio Pharmaceuticals, Inc. announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. This Phase 1 data was published in The Journal of Infectious Diseases and further supports the...
Merck , known as MSD outside the United States and Canada, and
NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has
exercised its option to extend the research phase of the companies'
broad, strategic collaboration...
The shareholders in Sandvik Aktiebolag are convened to the Annual General Meeting to be held on Monday, 29 April 2019 at 3:00 p.m. at the Göransson Arena, Sätragatan 21, Sandviken, Sweden.
RIGHT TO PARTICIPATE AND NOTICE
Shareholders who wish to...
The Oslo Business for Peace Award is given to inspiring business
leaders who have put society first.
2019's winners are: Dr Agbor Ashumanyi Ako,
medical director of GiftedMom, Alice Laugher, CEO of
Committed to...
The evolving competitive market has made it essential for the telecommunication industry to rethink traditional ways of doing business in terms of the impact on business models, service portfolios and technical architectures. Digital business support...